Product Description
Thalidomide is a medication used to manage and treat advanced leprosy and multiple myeloma, and various other solid and hematologic malignancies. It is in the immunomodulatory class of medications. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557706/)
Mechanisms of Action: Angiogenesis Inhibitor,TNF Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Estonia | European Medicines Agency | Finland | France | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Taiwan | Thailand | Turkey | Ukraine | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: Neuritis | Erythema | Erythema Nodosum | Multiple Myeloma
Known Adverse Events: Embolism | Embolism and Thrombosis | Embolism, Fat | Thrombosis | Confusion | Dizziness | Headache | Leukopenia | Muscle Weakness | Hypocalcemia | Dyspnea | Anorexia | Asthenia | Edema | Weight Gain | Weight Loss
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, China, Germany, Japan, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Epistaxis|Telangiectasia, Hereditary Hemorrhagic
Phase 2: Multiple Myeloma|Myelofibrosis|Spondylitis, Ankylosing
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2071230066 | P3 |
Not yet recruiting |
Telangiectasia, Hereditary Hemorrhagic|Epistaxis |
2025-11-30 |
|
| NCT03069326 | P2 |
Active, not recruiting |
Myelofibrosis |
2025-02-01 |
|
| AGMT_MM-2 | P2 |
Completed |
Multiple Myeloma |
2024-03-28 |
|
| AGMT_MM-2 | P2 |
Active, not recruiting |
Multiple Myeloma |
2023-08-18 |